Product Overview
[Drug Name]
Generic Name: Trimetazidine Hydrochloride Tablets
Trade Name: Runjiu Trimetazidine Hydrochloride Tablets 20mg*30 Tablets
[Main Ingredients]
Trimetazidine Hydrochloride Tablets
[Indications/Main Functions]
Preventive treatment of angina attacks. Adjunctive symptomatic treatment of vertigo and tinnitus.
[Specifications]
20mg*30 tablets (Runjiu)
[Dosage and Administration]
60mg every 24 hours: Take one tablet three times daily with meals. Evaluate the therapeutic effect after three months; discontinue the drug if no therapeutic effect is seen.
[Adverse Reactions]
Rare gastrointestinal discomfort (nausea, vomiting). Allergic reactions may occur due to the presence of Sunset Yellow FCFS (E110) and Carmine Red A (E124) in the excipients.
[Contraindications]
Contraindicated in patients with allergies to any of the drug's components. Use during lactation is generally not recommended (see [Use in Pregnant and Lactating Women]).
[Drug Interactions]
To avoid potential interactions between different medications, you must inform your doctor or pharmacist of any other treatments you are taking.
[Precautions]
This medication is not intended for symptomatic treatment of angina or for initial treatment of unstable angina or myocardial infarction. It should not be used for treatment before or during the first few days after hospitalization. During an angina attack, coronary artery disease should be reassessed, and treatment adjustments (medication and possible revascularization) should be considered.
[Pediatric Use]
The safety and effectiveness of this medication in children have not been established.
[Elderly Use]
See other sections or follow your doctor's advice.
[Overdose]
This medication should be taken exactly as prescribed. If you believe this medication is too strong or too weak, consult your doctor. If you suspect you have taken more than the prescribed dose, contact your doctor immediately. If you miss a dose, take the regular dose as directed for the next dose. Do not take a double dose to make up for a missed dose.
[Pharmacology and Toxicology]
This drug belongs to the other class of antianginal cardiovascular drugs. Trimetazidine protects cellular energy metabolism during hypoxia or ischemia by preventing the decline in intracellular ATP levels, thereby ensuring the normal function of ion pumps and transmembrane sodium-potassium flux, and maintaining a stable intracellular environment. Animal studies have shown that trimetazidine: - Helps maintain energy metabolism in the heart and sensory organs during ischemia and hypoxia. - Reduces intracellular acidosis and ischemia-induced changes in transmembrane ion flux. - Reduces the migration and infiltration of polynuclear neutrophils during ischemia and myocardial reperfusion, and reduces the size of experimental myocardial infarction. - This effect occurs without significant effects on hemodynamics. Human studies have shown that controlled trials in patients with angina pectoris have shown that trimetazidine: - Increases coronary blood flow reserve, thereby delaying the onset of exercise-induced ischemia starting from the 15th day of treatment. - Limits rapid fluctuations in blood pressure without significant changes in heart rate. Significantly reduce the frequency of angina attacks. Significantly reduce the consumption of nitroglycerin.
